These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 18649055)
1. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Oka H; Ikeda S; Koga S; Miyahara Y; Kohno S Heart Vessels; 2008 Jul; 23(4):249-56. PubMed ID: 18649055 [TBL] [Abstract][Full Text] [Related]
2. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Puccetti L; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Angori P; Auteri A; Bruni F Eur J Clin Invest; 2002 Dec; 32(12):901-8. PubMed ID: 12534449 [TBL] [Abstract][Full Text] [Related]
3. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. Atalar E; Ozmen F; Haznedaroglu I; Açil T; Ozer N; Ovünç K; Aksöyek S; Kes S Int J Cardiol; 2002 Aug; 84(2-3):227-31. PubMed ID: 12127376 [TBL] [Abstract][Full Text] [Related]
4. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882 [TBL] [Abstract][Full Text] [Related]
5. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). Liu PY; Lin LY; Lin HJ; Hsia CH; Hung YR; Yeh HI; Wu TC; Chen JY; Chien KL; Chen JW PLoS One; 2013; 8(10):e76298. PubMed ID: 24098467 [TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066 [TBL] [Abstract][Full Text] [Related]
8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Strandberg TE; Feely J; Sigurdsson EL; Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694 [TBL] [Abstract][Full Text] [Related]
9. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Pontrelli L; Parris W; Adeli K; Cheung RC Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170 [TBL] [Abstract][Full Text] [Related]
10. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study. Kucera M; Oravec S; Hirnerova E; Huckova N; Celecova Z; Gaspar L; Banach M Angiology; 2014 Oct; 65(9):794-9. PubMed ID: 24163116 [TBL] [Abstract][Full Text] [Related]
11. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. Labiós M; Martínez M; Gabriel F; Guiral V; Martínez E; Aznar J Thromb Res; 2005; 115(4):263-70. PubMed ID: 15668185 [TBL] [Abstract][Full Text] [Related]
12. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Heinonen TM; Stein E; Weiss SR; McKenney JM; Davidson M; Shurzinske L; Black DM Clin Ther; 1996; 18(5):853-63. PubMed ID: 8930429 [TBL] [Abstract][Full Text] [Related]
13. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
14. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J; Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589 [TBL] [Abstract][Full Text] [Related]
15. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Kural BV; Orem C; Uydu HA; Alver A; Orem A Coron Artery Dis; 2004 Aug; 15(5):277-83. PubMed ID: 15238825 [TBL] [Abstract][Full Text] [Related]
16. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients. Thallinger C; Urbauer E; Lackner E; Graselli U; Kostner K; Wolzt M; Joukhadar C Int J Clin Pharmacol Ther; 2005 Dec; 43(12):551-7. PubMed ID: 16372516 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813 [TBL] [Abstract][Full Text] [Related]
18. 3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects. Puccetti L; Pasqui AL; Pastorelli M; Ciani F; Palazzuoli A; Gioffrè W; Auteri A; Bruni F Atherosclerosis; 2005 Dec; 183(2):322-8. PubMed ID: 16285995 [TBL] [Abstract][Full Text] [Related]